AI-generated analysis. Always verify with the original filing.
CytoMed Therapeutics reported full-year 2025 financial results with revenue of US$780,857, net loss of US$3.11 million, and cash of US$1.63 million, alongside clinical trial progress and asset acquisitions.
Event Type
Disclosure
Voluntary
Variant
6-K
Current Report on Form 6-K
| Metric | Value | Basis |
|---|---|---|
| Total revenue and other operating income | $780.9K | |
| Net Loss | $3.1M | GAAP |
| Research Expenses | $1.7M | |
| Employee Benefits Expenses | $723.7K | |
| Other Expenses | $1.3M |